JPWO2019222154A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222154A5 JPWO2019222154A5 JP2021514291A JP2021514291A JPWO2019222154A5 JP WO2019222154 A5 JPWO2019222154 A5 JP WO2019222154A5 JP 2021514291 A JP2021514291 A JP 2021514291A JP 2021514291 A JP2021514291 A JP 2021514291A JP WO2019222154 A5 JPWO2019222154 A5 JP WO2019222154A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- ring
- pharmaceutically acceptable
- formula
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 108030001712 Macrophage elastases Proteins 0.000 claims description 4
- 206010061481 Renal injury Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 208000037806 kidney injury Diseases 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- -1 amino, hydroxyl Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- JFSPBVWPKOEZCB-UHFFFAOYSA-N fenfuram Chemical group O1C=CC(C(=O)NC=2C=CC=CC=2)=C1C JFSPBVWPKOEZCB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023142664A JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| US62/671,753 | 2018-05-15 | ||
| PCT/US2019/032127 WO2019222154A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023142664A Division JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523240A JP2021523240A (ja) | 2021-09-02 |
| JPWO2019222154A5 true JPWO2019222154A5 (https=) | 2022-05-11 |
| JP2021523240A5 JP2021523240A5 (https=) | 2022-05-11 |
| JP7344959B2 JP7344959B2 (ja) | 2023-09-14 |
Family
ID=66690981
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514292A Active JP7343571B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2021514291A Active JP7344959B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514292A Active JP7343571B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20190352288A1 (https=) |
| EP (4) | EP4335499A3 (https=) |
| JP (4) | JP7343571B2 (https=) |
| KR (3) | KR102861502B1 (https=) |
| CN (3) | CN112424186A (https=) |
| AU (3) | AU2019269409B2 (https=) |
| BR (1) | BR112020023269A2 (https=) |
| CA (2) | CA3100320A1 (https=) |
| DK (2) | DK3793995T3 (https=) |
| ES (2) | ES2978192T3 (https=) |
| FI (2) | FI3793992T3 (https=) |
| HU (2) | HUE066619T2 (https=) |
| LT (1) | LT3793995T (https=) |
| MY (1) | MY199200A (https=) |
| PL (1) | PL3793995T3 (https=) |
| PT (2) | PT3793992T (https=) |
| SG (2) | SG11202011316RA (https=) |
| SI (1) | SI3793995T1 (https=) |
| TW (3) | TWI827601B (https=) |
| WO (2) | WO2019222157A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| SI3793995T1 (sl) | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
| CA3158234A1 (en) * | 2019-11-14 | 2021-05-20 | Foresee Pharmaceuticals Co., Ltd. | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
| EP4351566A4 (en) * | 2021-06-08 | 2025-04-23 | Foresee Pharmaceuticals USA, Inc. | SAFE ADMINISTRATION OF MMP-12 INHIBITOR |
| TW202313011A (zh) * | 2021-06-08 | 2023-04-01 | 逸達生物科技股份有限公司 | Mmp抑制劑於治療急性呼吸窘迫綜合症之用途 |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| EP1150975A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| JP2004527511A (ja) | 2001-03-15 | 2004-09-09 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| JP5042833B2 (ja) | 2004-08-19 | 2012-10-03 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体 |
| EP2797002A4 (en) | 2011-12-21 | 2015-05-20 | Panasonic Corp | DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD |
| SI3793995T1 (sl) * | 2018-05-15 | 2024-05-31 | Foresee Pharmaceuticals Usa, Inc. | Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe |
-
2019
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 EP EP24150920.7A patent/EP4349332A3/en active Pending
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523240A5 (https=) | ||
| AU2009225374B2 (en) | Sodium channel blockers | |
| TWI768087B (zh) | 包含帕博西尼(palbociclib)及6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸的組合 | |
| JP6891286B2 (ja) | チューブリン阻害剤 | |
| JP2014503574A5 (https=) | ||
| JP2018188478A (ja) | 肝疾患を処置する方法 | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2017529382A (ja) | 治療活性を有する化合物及びその使用方法 | |
| CN119950536A (zh) | 用于治疗炎症疾病的喹啉衍生物 | |
| KR20170141757A (ko) | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 | |
| AU2008314979A1 (en) | Inhibitor of PAI-1 production | |
| JPWO2019222154A5 (https=) | ||
| KR20210003780A (ko) | Axl 키나제 억제제 및 그의 용도 | |
| JP2014502599A (ja) | チオセミカルバゾン化合物および癌の治療における使用 | |
| JP2021523241A5 (https=) | ||
| US20250090507A1 (en) | Methods of Treating Cancer With a B-RAF Inhibitor | |
| EP4129298B1 (en) | Composite pharmaceutical composition for treatment of fibrosis disease | |
| JP2024012474A (ja) | 重水素化イミダゾリジンジオン化合物とその用途 | |
| JPWO2019031470A1 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP6738350B2 (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
| WO2009018807A1 (de) | Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie | |
| CN118900691A (zh) | 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺及其衍生物与s1p受体调节剂的组合 | |
| US20210137905A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| CN120815086A (zh) | 联合用药的抗癌组合物、组合物在制备抗癌药物中的应用 | |
| CN106661060B (zh) | 菲罗啉膦酸类衍生物及其制备方法和应用 |